Divergent dysregulation of gene expression in murine models of fragile X syndrome and tuberous sclerosis

Molecular Autism

Volumn 5, Issue 1, 2014, Pages

  Kong, Sek Won ^a,c   Sahin, Mustafa ^a   Collins, Christin D ^a   Wertz, Mary H ^a   Campbell, Malcolm G ^c   Leech, Jarrett D ^a   Krueger, Dilja ^b   Bear, Mark F ^b   Kunkel, Louis M ^a   Kohane, Isaac S ^a,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c Harvard Medical School Center for Biomedical Informatics   (United States)

Author keywords

Autism; Blood; Cerebellum; Fragile X syndrome; Gene expression; Murine model; Tuberous sclerosis

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; GLYCOLIPID; LIGAND; PHOSPHATIDYLINOSITOL; RIBOSOME PROTEIN; TUBERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTISM; BLOOD; CEREBELLUM; CONTROLLED STUDY; FRAGILE X SYNDROME; GAP JUNCTION; GENE EXPRESSION; GENE INACTIVATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOSITY; IMMUNE RESPONSE; LIPID METABOLISM; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL PLASTICITY; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUBEROUS SCLEROSIS; VALIDATION PROCESS;

MURINAE; MUS;

EID: 84895919996     PISSN: None     EISSN: 20402392     Source Type: Journal    
DOI: 10.1186/2040-2392-5-16     Document Type: Article

References (54)

1. Risk factors for autism: translating genomic discoveries into diagnostics. Scherer SW, Dawson G, Hum Genet 2011 130 123 148 10.1007/s00439-011-1037-2 21701786
2. Solving the autism puzzle a few pieces at a time. Schaaf CP, Zoghbi HY, Neuron 2011 70 806 808 10.1016/j.neuron.2011.05.025 21658575
3. Advances in autism genetics: on the threshold of a new neurobiology. Abrahams BS, Geschwind DH, Nat Rev Genet 2008 9 341 355 10.1038/nrg2346 18414403
4. Maternal infection and immune involvement in autism. Patterson PH, Trends Mol Med 2011 17 389 394 10.1016/j.molmed.2011.03.001 21482187
5. Developmental neurotoxicity of industrial chemicals. Grandjean P, Landrigan PJ, Lancet 2006 368 2167 2178 10.1016/S0140-6736(06)69665-7 17174709
6. The co-morbidity burden of children and young adults with autism spectrum disorders. Kohane IS, McMurry A, Weber G, MacFadden D, Rappaport L, Kunkel L, Bickel J, Wattanasin N, Spence S, Murphy S, Churchill S, PLoS One 2012 7 33224 10.1371/journal.pone.0033224 22511918
7. Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Hagerman R, Hoem G, Hagerman P, Mol Autism 2010 1 12 10.1186/2040-2392-1-12 20858229
8. Annotation: tuberous sclerosis. Harrison JE, Bolton PF, J Child Psychol Psychiatry 1997 38 603 614 10.1111/j.1469-7610.1997.tb01687.x 9315970
9. Behavioural phenotyping assays for mouse models of autism. Silverman JL, Yang M, Lord C, Crawley JN, Nat Rev Neurosci 2010 11 490 502 10.1038/nrn2851 20559336
10. Behavioral profiles of mouse models for autism spectrum disorders. Ey E, Leblond CS, Bourgeron T, Autism Research 2011 4 5 16 10.1002/aur.175 21328568
11. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nie D, Di Nardo A, Han JM, Baharanyi H, Kramvis I, Huynh T, Dabora S, Codeluppi S, Pandolfi PP, Pasquale EB, Sahin M, Nat Neurosci 2010 13 163 172 10.1038/nn.2477 20062052
12. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ, Nat Med 2008 14 843 848 10.1038/nm1788 18568033
13. Therapeutic implications of the mGluR theory of fragile X mental retardation. Bear MF, Genes Brain Behav 2005 4 393 398 10.1111/j.1601-183X.2005. 00135.x 16098137
14. Consensus paper: pathological role of the cerebellum in autism. Fatemi SH, Aldinger KA, Ashwood P, Bauman ML, Blaha CD, Blatt GJ, Chauhan A, Chauhan V, Dager SR, Dickson PE, Estes AM, Goldowitz D, Heck DH, Kemper TL, King BH, Martin LA, Millen KJ, Mittleman G, Mosconi MW, Persico AM, Sweeney JA, Webb SJ, Welsh JP, Cerebellum 2012 11 777 807 10.1007/s12311-012-0355-9 22370873
15. Characterization of autism in young children with tuberous sclerosis complex. Jeste SS, Sahin M, Bolton P, Ploubidis GB, Humphrey A, J Child Neurol 2008 23 520 525 10.1177/0883073807309788 18160549
16. Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex. Tsai P, Sahin M, Curr Opin Neurol 2011 24 106 113 10.1097/WCO.0b013e32834451c4 21301339
17. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, Eng C, J Med Genet 2005 42 318 321 10.1136/jmg.2004.024646 15805158
18. A mutant form of PTEN linked to autism. Redfern RE, Daou MC, Li L, Munson M, Gericke A, Ross AH, Protein Sci 2010 19 1948 1956 10.1002/pro.483 20718038
19. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. McBride KL, Varga EA, Pastore MT, Prior TW, Manickam K, Atkin JF, Herman GE, Autism Res 2010 3 137 141 10.1002/aur.132 20533527
20. Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. Cusco I, Medrano A, Gener B, Vilardell M, Gallastegui F, Villa O, Gonzalez E, Rodriguez-Santiago B, Vilella E, Del Campo M, Perez-Jurado LA, Hum Mol Genet 2009 18 1795 1804 10.1093/hmg/ddp092 19246517
21. The autistic neuron: troubled translation? Kelleher RJ, Bear MF, Cell 2008 135 401 406 10.1016/j.cell.2008.10.017 18984149
22. Deregulation of EIF4E: a novel mechanism for autism. Neves-Pereira M, Muller B, Massie D, Williams JH, O'Brien PC, Hughes A, Shen SB, Clair DS, Miedzybrodzka Z, J Med Genet 2009 46 759 765 10.1136/jmg.2009.066852 19556253
23. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Bromley RL, Mawer G, Clayton-Smith J, Baker GA, Neurology 2008 71 1923 1924 10.1212/01.wnl.0000339399.64213.1a 19047565
24. Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. Gurpur PB, Liu J, Burkin DJ, Kaufman SJ, Am J Pathol 2009 174 999 1008 10.2353/ajpath.2009.080537 19179609
25. Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Dufour-Rainfray D, Vourc'h P, Le Guisquet AM, Garreau L, Ternant D, Bodard S, Jaumain E, Gulhan Z, Belzung C, Andres CR, Chalon S, Guilloteau D, Neurosci Lett 2010 470 55 59 10.1016/j.neulet.2009.12. 054 20036713
26. Dysregulation of mTOR signaling in fragile X syndrome. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, Zukin RS, J Neurosci 2010 30 694 702 10.1523/JNEUROSCI.3696-09.2010 20071534
27. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, Warren ST, Bassell GJ, J Neurosci 2010 30 10624 10638 10.1523/JNEUROSCI.0402-10.2010 20702695
28. Differential translation and fragile X syndrome. Vanderklish PW, Edelman GM, Genes Brain Behav 2005 4 360 384 10.1111/j.1601-183X.2005.00134.x 16098135
29. Neuroanatomy of autism. Amaral DG, Schumann CM, Nordahl CW, Trends Neurosci 2008 31 137 145 10.1016/j.tins.2007.12.005 18258309
30. Neuroanatomic observations of the brain in autism: a review and future directions. Bauman ML, Kemper TL, Int J Dev Neurosci 2005 23 183 187 10.1016/j.ijdevneu.2004.09.006 15749244
31. How the brain processes social information: searching for the social brain. Insel TR, Fernald RD, Annu Rev Neurosci 2004 27 697 722 10.1146/annurev.neuro.27.070203.144148 15217348
32. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Tsai PT, Hull C, Chu Y, Greene-Colozzi E, Sadowski AR, Leech JM, Steinberg J, Crawley JN, Regehr WG, Sahin M, Nature 2012 488 647 651 10.1038/nature11310 22763451
33. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Huber KM, Gallagher SM, Warren ST, Bear MF, Proc Natl Acad Sci USA 2002 99 7746 7750 10.1073/pnas.122205699 12032354
34. Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. Onda H, Lueck A, Marks PW, Warren HB, Kwiatkowski DJ, J Clin Invest 1999 104 687 695 10.1172/JCI7319 10491404
35. Characteristics and predictive value of blood transcriptome signature in males with autism spectrum disorders. Kong SW, Collins CD, Shimizu-Motohashi Y, Holm IA, Campbell MG, Lee IH, Brewster SJ, Hanson E, Harris HK, Lowe KR, Saada A, Mora A, Madison K, Hundley R, Egan J, McCarthy J, Eran A, Galdzicki M, Rappaport L, Kunkel LM, Kohane IS, PLoS One 2012 7 49475 10.1371/journal.pone. 0049475 23227143
36. Statistical significance for genomewide studies. Storey JD, Tibshirani R, Proc Natl Acad Sci USA 2003 100 9440 9445 10.1073/pnas.1530509100 12883005
37. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Proc Natl Acad Sci USA 2005 102 15545 15550 10.1073/pnas.0506580102 16199517
38. AutDB: a gene reference resource for autism research. Basu SN, Kollu R, Banerjee-Basu S, Nucleic Acids Res 2009 37 832 D836 10.1093/nar/gkn835 19015121
39. In silico analysis of the EPS8 gene family: genomic organization, expression profile, and protein structure. Tocchetti A, Confalonieri S, Scita G, Di Fiore PP, Betsholtz C, Genomics 2003 81 234 244 10.1016/S0888-7543(03)00002- 8 12620401
40. FMRP targets distinct mRNA sequence elements to regulate protein expression. Ascano M Jr, Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, Langlois C, Munschauer M, Dewell S, Hafner M, Williams Z, Ohler U, Tuschl T, Nature 2012 492 382 386 10.1038/nature11737 23235829
41. Activity-dependent spine morphogenesis: a role for the actin-capping protein Eps8. Stamatakou E, Marzo A, Gibb A, Salinas PC, J Neurosci 2013 33 2661 2670 10.1523/JNEUROSCI.0998-12.2013 23392693
42. Eps8 controls dendritic spine density and synaptic plasticity through its actin-capping activity. Menna E, Zambetti S, Morini R, Donzelli A, Disanza A, Calvigioni D, Braida D, Nicolini C, Orlando M, Fossati G, Cristina Regondi M, Pattini L, Frassoni C, Francolini M, Scita G, Sala M, Fahnestock M, Matteoli M, EMBO J 2013
43. The multiple facets of mTOR in immunity. Weichhart T, Saemann MD, Trends Immunol 2009 30 218 226 10.1016/j.it.2009.02.002 19362054
44. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, Squillace R, Kwiatkowski DJ, Am J Respir Cell Mol Biol 2010 42 227 234 10.1165/rcmb.2009-0050OC 19395678
45. Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice. Ehninger D, Sano Y, de Vries PJ, Dies K, Franz D, Geschwind DH, Kaur M, Lee YS, Li W, Lowe JK, Nakagawa JA, Sahin M, Smith K, Whittemore V, Silva AJ, Mol Psychiatry 2012 17 62 70 10.1038/mp.2010.115 21079609
46. Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis? Ashwood P, Nguyen DV, Hessl D, Hagerman RJ, Tassone F, Brain Behav Immun 2010 24 898 902 10.1016/j.bbi.2010.01.008 20102735
47. Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of fragile X syndrome. Yuskaitis CJ, Beurel E, Jope RS, Biochim Biophys Acta 2010 1802 1006 1012 10.1016/j.bbadis.2010.06.015 20600866
48. S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. Narayanan U, Nalavadi V, Nakamoto M, Thomas G, Ceman S, Bassell GJ, Warren ST, J Biol Chem 2008 283 18478 18482 10.1074/jbc.C800055200 18474609
49. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Auerbach BD, Osterweil EK, Bear MF, Nature 2011 480 63 68 10.1038/nature10658 22113615
50. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Tavazoie SF, Alvarez VA, Ridenour DA, Kwiatkowski DJ, Sabatini BL, Nat Neurosci 2005 8 1727 1734 10.1038/nn1566 16286931
51. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, Greenough WT, Proc Natl Acad Sci U S A 1997 94 5401 5404 10.1073/pnas.94.10.5401 9144249
52. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO, Cantley LC, Blenis J, Mol Cell 2010 38 487 499 10.1016/j.molcel.2010.05.007 20513425
53. A blood gene expression marker of early Alzheimer's disease. Lunnon K, Sattlecker M, Furney SJ, Coppola G, Simmons A, Proitsi P, Lupton MK, Lourdusamy A, Johnston C, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Geschwind D, Lovestone S, Dobson R, Hodges A, dNeuroMed Consortium, J Alzheimers Dis 2013 33 737 753 23042217
54. A null mutation for Fmr1 in female mice: effects on regional cerebral metabolic rate for glucose and relationship to behavior. Qin M, Kang J, Smith CB, Neuroscience 2005 135 999 1009 10.1016/j.neuroscience.2005.06.081 16154294